CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss ... of Medicine showing ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.